cellTranspl.ru - Autogenic IL-10 modified dendritic cells in immunetherapy of multiplesclerosis: the first clinical experience

Autogenic IL-10 modified dendritic cells in immunetherapy of multiplesclerosis: the first clinical experience

PDF, Volume III, №4, 2008

M.M. Odinak¹, V.S. Chirsky¹, G.N. Bisaga¹, I.A. Baldueva², V.M. Moiseenko², T.L. Nekhaeva², N.M. Kalinina³, N.I. Davydova³, N.V. Bychkova³, C. Ciumas⁴

1. S.M. Kirov Military Medical academy, Saint Petersburg, Russia
2. N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russia
3. Nikiforov Russian Center of Emergency and Radiation Medicine, Saint Petersburg, Russia
4. Epilepsy Research Center, Lyon, France

Keywords:
multiple sclerosis, dendritic cells, immune tolerance

Рейтинг: 0.00 Оцените статью: 1 2 3 4 5 Просмотров: 1204, комментариев: 0

The search of effective therapy for multiple sclerosis (MS) that is the most common demyelinating disorder of the central nervous system af fecting young people leading to their disability isstillactual. The cumulative data as well as clinical experience of dendritic cells (DCs) usage in oncology facilitated a pilot investigation - a clinical study of the I phase of autogenic IL-10 modified DCs usage in immune therapy of MS. A course of experimental immune therapy was given to a 46 year old man with secondary progressive MS who had failed to respond to combined treatment including specific standard immune therapy with copaxone and nonspecific antioxidant neuroprotective and corticosteroid therapy. A single dose of autogenic IL-10 modified dendritic cells in the amount of 3×10⁶ was injected subcutaneously into the patients back and was thrice-repeated in 4 months at successive intervals of a month. The first results showed that in the absence of any local side effects the immune system response to the administration of these cells was rather complex with the participation of T- and B- cells. The decline of the antibody titres to myelin basic protein was most significant that can be considered as an evidence of formation of immune tolerance to this protein along with relative and absolute increase of a peripheral blood regulatory T-lymphocytes (CD4+CD25+) number. However, relevant alterations of the patients clinical and neurologic status did not occur after the course of autogenic IL-10 modified DCs had been given. The data received allow to consider further investigations of the proposed method of specific immune therapy appropriate in order to assess its tolerance, safety and mechanisms of DCs ef fects on patients with MS.

1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2001; 22(2): 117-39.
2. Hernandes M.A. Epidemiology of multiple sclerosis. Controversies and realities. Rev. Neurol. 2000; 30(10): 959-64.
3. Trapp B.D., Peterson J., Ransohoff R.M. et al. Axonal transection in the lesions of multiple sclerosis. N. Ingl. J. Med. 1998; 338(5): 278-85.
4. Fox R.J., Cohen J.A. Multiple sclerosis: the importance of early recognition and treatment. Cleve. Clin. J. Med. 2001; 68: 157-71.
5. Xiao B.G., Huang Y.M., Link H. Tolerogenic Dendritic Cells: The Ins and Outs of Outcome J. Immunother. 2006; 29: 465-71.
6. Stbve 0., Cravens P.D., EagarT.N. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 2008; 8: 351-60.
7. Duan R.S., Link H., Xiao B.G. Long-term effects of IFN-y, IL-10 and TGF-p-modulated dendritic cells on immune response in Lewis rats. J. Clin. Immunol. 2005; 25: 50-5.
8. Moiseenko V.M., Baldueva I.A., Orlova R.V., Semenova A.I. Sposob immunoterapii kostno-mozgovymi dendritnymi kletkami bol'nyh solidnymi opuholyami. Avtorskoe svidetel'stvo na izobretenie № 2203683.
9. Baldueva I.A. Protivoopuholevye vakciny. Prakticheskaya onkologiya 2003; 3: 157-66.
10. Moiseenko V.M., Baldueva I.A., Danilova A.B. i dr. Shestiletnij opyt vakcinoterapii zlokachestvennyh opuholej. Med. immunologiya 2004; 6(Z-5): 458.
11. Steinbrink К., Wolfl M., Jonuleit H. et al. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997; 159: 4772-80.
12. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003; 21: 685-711.
13. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445-9.
14. Taams L.S., Akbar A.N. Peripheral generation and function of CD4+CD25+ regulatory T cells. Curr. Top Microbiol. Immunol. 2005; 293: 115-31.
15. Serody J.S., Collins E.J., Tisch R.M. et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 2000; 164: 4961-7.
16. Corinti S., Albanesi C, la Sala A. et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 2001; 166: 4312-4318.
17. RutellaS., BonannoG., Pierelli L. etal. Granulocyte colonystimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur. J. Immunol. 2004; 34: 1291-302.